PTGS2 and Alzheimer disease: In addition, administration of the COX-2 inhibitor rofecoxib (3 mg kg−1 day−1, 7 days) attenuates the inflammatory response and neurodegeneration evoked by Aβ1–42 in AD rats (Giovannini et al., 2002).